- Home
- GDEN vs ABUS Comparison
GDEN vs ABUS Comparison
Compare GDEN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- ABUS
- Stock Information
- Founded
- GDEN 1998
- ABUS 2005
- Country
- GDEN United States
- ABUS United States
- Employees
- GDEN N/A
- ABUS N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- ABUS Health Care
- Exchange
- GDEN Nasdaq
- ABUS Nasdaq
- Market Cap
- GDEN 727.9M
- ABUS 611.0M
- IPO Year
- GDEN 1999
- ABUS N/A
- Fundamental
- Price
- GDEN $29.05
- ABUS $3.23
- Analyst Decision
- GDEN Buy
- ABUS Strong Buy
- Analyst Count
- GDEN 6
- ABUS 4
- Target Price
- GDEN $36.50
- ABUS $5.50
- AVG Volume (30 Days)
- GDEN 187.8K
- ABUS 818.8K
- Earning Date
- GDEN 08-07-2025
- ABUS 07-31-2025
- Dividend Yield
- GDEN 3.49%
- ABUS N/A
- EPS Growth
- GDEN N/A
- ABUS N/A
- EPS
- GDEN 0.39
- ABUS N/A
- Revenue
- GDEN $653,614,000.00
- ABUS $6,403,000.00
- Revenue This Year
- GDEN $1.48
- ABUS $3.35
- Revenue Next Year
- GDEN $2.88
- ABUS N/A
- P/E Ratio
- GDEN $73.75
- ABUS N/A
- Revenue Growth
- GDEN N/A
- ABUS N/A
- 52 Week Low
- GDEN $22.66
- ABUS $2.71
- 52 Week High
- GDEN $35.49
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- GDEN 46.02
- ABUS 49.68
- Support Level
- GDEN $28.31
- ABUS $3.08
- Resistance Level
- GDEN $32.74
- ABUS $3.20
- Average True Range (ATR)
- GDEN 1.03
- ABUS 0.11
- MACD
- GDEN -0.37
- ABUS 0.00
- Stochastic Oscillator
- GDEN 16.70
- ABUS 53.57
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.